Literature DB >> 20721462

Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery.

Silvania Klug Pimentel1, Rodrigo Strobel, Carolina Gomes Gonçalves, Danielle Giacometti Sakamoto, Flávio Heuta Ivano, Júlio Cezar Uili Coelho.   

Abstract

CONTEXT: Morbidly obese patients have an increased risk for nonalcoholic fat liver disease. Its severe form, nonalcoholic steatohepatitis may cause liver fibrosis. The diagnosis of advanced fibrosis has great value during the pre operative evaluation for bariatric surgery. Currently, liver biopsy is the gold standard for diagnosis of liver fibrosis.
OBJECTIVE: To evaluate the nonalcoholic fat liver disease fibrosis score in morbidly obese patients undergoing Roux-en-Y gastric bypass in our population.
METHODS: One hundred fifty-eight morbidly obese patients that had undergone bariatric surgery were included. Age, body mass index, hyperglycemia, platelet count, albumin and AST/ALT ratio were applied to the score formula. Scores above 0.676 were indicative of advanced liver fibrosis and scores under -1,455 absence of advanced liver fibrosis. These scores were compared to liver biopsy findings.
RESULTS: The presence of advanced fibrosis could be diagnosed with good accuracy, with a positive predictive value of 83.7%. The score had a higher accuracy to exclude advanced fibrosis with a negative predictive value of 97%. Twenty-five patients (16%) had scores between the cutoffs points and were identified as indeterminate. The score sensibility and specificity was 83% and 97% respectively.
CONCLUSIONS: The nonalcoholic fat liver disease fibrosis score has high accuracy to identify and exclude advanced liver fibrosis in morbidly obese patients subjected to bariatric surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721462     DOI: 10.1590/s0004-28032010000200010

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  5 in total

1.  Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study.

Authors:  Everton Cazzo; Laísa Simakawa Jimenez; José Carlos Pareja; Elinton Adami Chaim
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

2.  Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery?

Authors:  Kerri A Simo; Iain H McKillop; Matthew T McMillan; William A Ahrens; Amanda L Walters; Kyle J Thompson; Timothy S Kuwada; John B Martinie; David A Iannitti; Keith S Gersin; David Sindram
Journal:  Obes Surg       Date:  2014-01       Impact factor: 4.129

Review 3.  KASL clinical practice guidelines: management of nonalcoholic fatty liver disease.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2013-12-28

4.  Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.

Authors:  Sami Qadri; Noora Ahlholm; Ida Lønsmann; Paola Pellegrini; Anni Poikola; Panu K Luukkonen; Kimmo Porthan; Anne Juuti; Henna Sammalkorpi; Anne K Penttilä; Roberta D'Ambrosio; Giorgio Soardo; Diana J Leeming; Morten Karsdal; Johanna Arola; Stergios Kechagias; Serena Pelusi; Mattias Ekstedt; Luca Valenti; Hannes Hagström; Hannele Yki-Järvinen
Journal:  J Clin Endocrinol Metab       Date:  2022-04-19       Impact factor: 6.134

5.  COMPARISON OF HEPATIC PROFILE IN PRE AND POSTOPERATIVE OF BARIATRIC SURGERY: PRIVATE VS PUBLIC NETWORK.

Authors:  Taianne Machado Nascimento; Antônio Alves-Júnior; Marco Antonio Prado Nunes; Tiago Rodrigo Pereira de Freitas; Marco Antonio Fontes Sarmento da Silva; Maria Rosa Melo Alves
Journal:  Arq Bras Cir Dig       Date:  2015 Nov-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.